STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 173154

TO: Robert J Balls **Location: 4d78 / 4c70** **Art Unit: 1625** **Tuesday, January 31, 2006** **Case Serial Number: 10/826136**	**From: Noble Jarrell** **Location: Biotech-Chem Library** **Rem 1B71** **Phone: 272-2556** **Noble.jarrell@uspto.gov**

Search Notes

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: James Balls Examiner #: 82049 Date: 31 Jan 2006
Art Unit: 1625 Phone Number: 2- Serial Number: 10/826,136
Location (Bldg/Room#): 4D78 (Mailbox #): 4C70 Results Format Preferred (circle): (PAPER) DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): Robert Hofgen

_____

Earliest Priority Date: _____

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

****

STAFF USE ONLY

Searcher: NOBLE
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: 1/31/06
Date Completed: 1/31/06
Searcher Prep & Review Time: 10
Online Time: 71

Type of Search

_____ NA Sequence (#)
_____ AA Sequence (#)
3 Structure (#)
✓ Bibliographic
_____ Litigation
_____ Fulltext
_____ Other

Vendors and cost where applicable

✓ STN _____ Dialog
_____ Questel/Orbit _____ Lexis/Nexis
_____ Westlaw _____ WWW/Internet
____ In-house sequence systems
____ Commercial ____ Oligomer ____ Score/Length
____ Interference ____ SPDI ____ Encode/Transl
_____ Other (specify)

```
=> b reg
FILE 'REGISTRY' ENTERED AT 13:08:09 ON 31 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 JAN 2006  HIGHEST RN 873057-98-8
DICTIONARY FILE UPDATES:  30 JAN 2006  HIGHEST RN 873057-98-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta l17
L15             STR

 N~~O        N---Ak
@10 11      @23 24
```




```
VAR G1=N/10
VAR G2=C/N/10
VAR G3=NH/23
NODE ATTRIBUTES:
CONNECT IS E1  RC AT  21
CONNECT IS E1  RC AT  22
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
```

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L17 52 SEA FILE=REGISTRY SSS FUL L15

100.0% PROCESSED 55 ITERATIONS 52 ANSWERS
SEARCH TIME: 00.00.01

=> d que sta l25
L23 STR



VAR G1=N/10
VAR G2=C/N/10
VAR G4=7/8
VAR G5=15/16/17
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L25 98 SEA FILE=REGISTRY SSS FUL L23

100.0% PROCESSED 199771 ITERATIONS 98 ANSWERS
SEARCH TIME: 00.00.13

=> d que sta l37
L23 STR



VAR G1=N/10
VAR G2=C/N/10
VAR G4=7/8
VAR G5=15/16/17
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE
L25 98 SEA FILE=REGISTRY SSS FUL L23
L34 STR



VAR G1=N/10
VAR G4=7/8
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 27
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L36 101 SEA FILE=REGISTRY SSS FUL L34
L37 3 SEA FILE=REGISTRY ABB=ON PLU=ON L36 NOT L25

=> b hcap
FILE 'HCAPLUS' ENTERED AT 13:08:46 ON 31 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 31 Jan 2006 VOL 144 ISS 6
FILE LAST UPDATED: 30 Jan 2006 (20060130/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> => d all hitstr l41 1-2

L41 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1037098 HCAPLUS
DN 143:347150
ED Entered STN: 28 Sep 2005
TI Preparation of pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
IN Salom, Barbara; D'Anello, Matteo; Brasca, Maria Gabriella; Giordano,
Patrizia; Martina, Katia; Angelucci, Francesco; Brookfield, Frederick

Arthur; Trigg, William John; Boyd, Edward Andrew; Larard, Jonathan Anthony
PA Pharmacia Italia S.p.A., Italy
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
IC C07D-0471/04; A61K-0031/437
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005063746	A1	20050714	2004WO-XC14674	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO2005063746	A1	20050714	2004WO-EP14674	20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI 2003GB-0030043	A	20031224		
2004WO-EP14674	A	20041223		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005063746	IC	C07D-0471/04; A61K-0031/437
	IPCI	C07D0471-04 [ICM]; A61K0031-437 [ICS]
	ECLA	C07D471/04+221B+209B
WO2005063746	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]
	ECLA	C07D471/04+221B+209B

GI



I



II

AB The title compds. [I; R = Ra, CORa, CONRaRb, SO2Ra, CO2Ra; R1 = NRcRd, ORc; Ra, Rb, Rc and Rd = H, alkyl, cycloalkyl, etc.] and pharmaceutically acceptable salts thereof together with pharmaceutical compns. comprising them, as well as combinatorial libraries of compds. I, are disclosed. Preparation of compds. I is described in eleven synthetic examples. E.g., a multi-step synthesis of II, starting from 5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid and isoamylamine-bearing resin, was given. The compds. I or compns. comprising them may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity (no biol. data given) such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders. Also disclosed is a process under SPS conditions for preparing the compds. I and chemical libraries comprising a plurality of them. This is a Part IV of I-IV series.

ST pyrrolopyridine prepn protein kinase inhibitor antitumor antiproliferative antiviral; Alzheimer disease pyrrolopyridine prepn; neurodegenerative disorder pyrrolopyridine prepn; combinatorial library pyrrolopyridine prepn protein kinase inhibitor

IT Sarcoma
(Kaposi's, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Antiarteriosclerotics
(antiatherosclerotics, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Prostate gland, disease
(benign hyperplasia, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hyperplasia
(benign prostatic, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, disease
(degeneration, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Lung, disease
(fibrosis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Thyroid gland, neoplasm
(follicle cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Chemotherapy
Radiotherapy
(for augmentation of; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Inflammation

Kidney, disease
(glomerulonephritis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Transplant and Transplantation
(host-vs.-graft reaction; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Hematopoietic precursor cell
(lymphoid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Neoplasm
(mesenchymal, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Neoplasm
(metastasis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Endocrine system, neoplasm
Neoplasm
(multiple endocrine neoplasia, treating familial adenomatosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Hematopoietic precursor cell
(myeloid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Mesenchyme
(neoplasm, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Nervous system, neoplasm
(neurofibromatosis type 1, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Bone, neoplasm
Sarcoma
(osteosarcoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Digestive tract, neoplasm
(polyposis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Antitumor agents
Antiviral agents
Cell proliferation
Combination chemotherapy
Combinatorial chemistry
Combinatorial library
Human
Immunomodulators
Immunosuppressants
Nervous system agents
Solid phase synthesis
Transplant rejection
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Fibrosis
(pulmonary, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Artery, disease
(restenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Testis, neoplasm
(seminoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Blood vessel
(smooth muscle, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Carcinoma
(squamous cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as

kinase inhibitors)
IT Artery, disease
(stenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Carcinoma
(teratocarcinoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Alopecia
(treating or preventing radiotherapy-induced or chemotherapy-induced alopecia; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Atherosclerosis
(treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Alzheimer's disease
Antiarthritics
Arthritis
Autoimmune disease
Carcinoma
Melanoma
Nervous system, neoplasm
Psoriasis
(treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Infection
(viral, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Skin, disease
(xanthoma, treating keratoxanthoma; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT Skin, disease
(xeroderma pigmentosum, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT 372092-80-3, Protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
IT 865839-17-4P 865839-18-5P 865839-19-6P 865839-20-9P 865839-21-0P
865839-22-1P 865839-23-2P 865839-24-3P 865839-25-4P 865839-26-5P
865839-27-6P 865839-28-7P 865839-29-8P 865839-30-1P 865839-31-2P
865839-32-3P 865839-33-4P 865839-34-5P 865839-35-6P 865839-36-7P
865839-37-8P 865839-38-9P 865839-39-0P 865839-40-3P 865839-41-4P
865839-42-5P 865839-43-6P 865839-44-7P 865839-45-8P 865839-46-9P
865839-47-0P 865839-48-1P 865839-51-6P 865839-52-7P 865839-53-8P
865839-54-9P 865839-55-0P 865839-56-1P 865839-57-2P 865839-58-3P
865839-59-4P 865839-60-7P 865839-61-8P 865839-62-9P 865839-63-0P
865839-64-1P 865839-65-2P 865839-66-3P 865839-67-4P 865839-68-5P
865839-69-6P 865839-70-9P 865839-71-0P 865839-72-1P 865839-73-2P
865839-74-3P 865839-75-4P 865839-76-5P 865839-77-6P 865839-78-7P
865839-79-8P 865839-80-1P 865839-81-2P 865839-82-3P 865839-83-4P
865839-84-5P 865839-85-6P 865839-86-7P 865839-87-8P 865839-88-9P
865839-89-0P 865839-91-4P 865839-92-5P 865839-93-6P 865839-94-7P
865839-95-8P 865839-97-0P 865840-00-2P 865840-03-5P 865840-04-6P
865840-05-7P 865840-08-0P 865840-11-5P 865840-12-6P 865840-13-7P
865840-14-8P 865840-15-9P 865840-16-0P 865840-17-1P 865840-18-2P
865840-19-3P 865840-20-6P 865840-21-7P 865840-22-8P 865840-23-9P
865840-24-0P 865840-25-1P 865840-26-2P 865840-27-3P 865840-28-4P
865840-29-5P 865840-30-8P 865840-31-9P 865840-32-0P 865840-33-1P
865840-34-2P 865840-35-3P 865840-36-4P 865840-38-6P 865840-39-7P
865840-40-0P 865840-41-1P 865840-42-2P 865840-43-3P 865840-44-4P
865840-45-5P 865840-46-6P 865840-47-7P 865840-48-8P 865840-49-9P
865840-50-2P 865840-51-3P 865840-52-4P 865840-53-5P 865840-54-6P
865840-55-7P 865840-56-8P 865840-57-9P 865840-58-0P 865840-59-1P
865840-60-4P 865840-61-5P 865840-62-6P 865840-63-7P 865840-64-8P
865840-65-9P 865840-66-0P 865840-67-1P 865840-68-2P 865840-69-3P
865840-70-6P 865840-71-7P 865840-72-8P 865840-73-9P 865840-74-0P

865840-75-1P 865840-76-2P 865840-78-4P 865840-79-5P 865840-80-8P
865840-81-9P 865840-82-0P 865840-83-1P 865840-84-2P 865840-85-3P
865840-86-4P 865840-87-5P 865840-88-6P 865840-89-7P 865840-90-0P
865840-91-1P 865840-92-2P 865840-93-3P 865840-94-4P 865840-95-5P
865840-96-6P 865840-97-7P 865840-98-8P 865840-99-9P 865841-00-5P
865841-01-6P 865841-02-7P 865841-03-8P 865841-04-9P 865841-05-0P
865841-06-1P 865841-07-2P 865841-08-3P 865841-09-4P 865841-10-7P
865841-11-8P 865841-12-9P 865841-14-1P 865841-15-2P 865841-16-3P
865841-17-4P 865841-18-5P 865841-19-6P 865841-20-9P 865841-21-0P
865841-22-1P 865841-23-2P 865841-24-3P 865841-25-4P 865841-26-5P
865841-27-6P 865841-28-7P 865841-29-8P 865841-30-1P 865841-31-2P
865841-32-3P 865841-33-4P 865841-34-5P 865841-35-6P 865841-36-7P
865841-37-8P 865841-38-9P 865841-39-0P 865841-40-3P 865841-41-4P
865841-42-5P 865841-43-6P 865841-44-7P 865841-45-8P 865841-46-9P
865841-48-1P 865841-49-2P 865841-50-5P 865841-51-6P 865841-52-7P
865841-53-8P 865841-54-9P 865841-55-0P 865841-56-1P 865841-57-2P
865841-58-3P 865841-59-4P 865841-60-7P 865841-61-8P 865841-62-9P
865841-63-0P 865841-64-1P 865841-65-2P 865841-66-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865841-67-4P 865841-68-5P 865841-69-6P 865841-70-9P 865841-71-0P
865841-72-1P 865841-73-2P 865841-74-3P 865841-75-4P 865841-76-5P
865841-77-6P 865841-78-7P 865841-79-8P 865841-80-1P 865841-81-2P
865841-82-3P 865841-83-4P 865841-84-5P 865841-86-7P 865841-87-8P
865841-88-9P 865841-89-0P 865841-90-3P 865841-91-4P 865841-92-5P
865841-93-6P 865841-94-7P 865841-95-8P 865841-96-9P 865841-97-0P
865841-98-1P 865841-99-2P 865842-00-8P 865842-01-9P 865842-02-0P
865842-03-1P 865842-04-2P 865842-05-3P 865842-06-4P 865842-07-5P
865842-08-6P 865842-09-7P 865842-10-0P 865842-11-1P 865842-12-2P
865842-13-3P 865842-14-4P 865842-15-5P 865842-16-6P 865842-17-7P
865842-18-8P 865842-19-9P 865842-20-2P 865842-21-3P 865842-22-4P
865842-23-5P 865842-24-6P 865842-25-7P 865842-26-8P 865842-27-9P
865842-28-0P 865842-29-1P 865842-30-4P 865842-31-5P 865842-32-6P
865842-33-7P 865842-34-8P 865842-35-9P 865842-36-0P 865842-37-1P
865842-38-2P 865842-39-3P 865842-40-6P 865842-41-7P 865842-42-8P
865842-43-9P 865842-44-0P 865842-45-1P 865842-46-2P 865842-47-3P
865842-48-4P 865842-49-5P 865842-50-8P 865842-51-9P 865842-52-0P
865842-53-1P 865842-54-2P 865842-55-3P 865842-56-4P 865842-57-5P
865842-58-6P 865842-59-7P 865842-60-0P 865842-61-1P 865842-62-2P
865842-63-3P 865842-64-4P 865842-65-5P 865842-66-6P 865842-67-7P
865842-68-8P 865842-69-9P 865842-70-2P 865842-71-3P 865842-72-4P
865842-73-5P 865842-74-6P 865842-75-7P 865842-76-8P 865842-77-9P
865842-78-0P 865842-79-1P 865842-80-4P 865842-81-5P 865842-82-6P
865842-83-7P 865842-84-8P 865842-85-9P 865842-86-0P 865842-87-1P
865842-88-2P 865842-89-3P 865842-90-6P 865842-91-7P 865842-92-8P
865842-93-9P 865842-94-0P 865842-95-1P 865842-96-2P 865842-97-3P
865842-98-4P 865842-99-5P 865843-00-1P 865843-01-2P 865843-02-3P
865843-03-4P 865843-04-5P 865843-05-6P 865843-06-7P 865843-07-8P
865843-08-9P 865843-09-0P 865843-10-3P 865843-11-4P 865843-12-5P
865843-13-6P 865843-14-7P 865843-15-8P 865843-16-9P 865843-17-0P
865843-18-1P 865843-19-2P 865843-20-5P 865843-21-6P 865843-22-7P
865843-23-8P 865843-25-0P 865843-26-1P 865843-27-2P 865843-28-3P
865843-29-4P 865843-30-7P 865843-31-8P 865843-32-9P 865843-33-0P
865843-34-1P 865843-35-2P 865843-36-3P 865843-37-4P 865843-38-5P
865843-39-6P 865843-40-9P 865843-41-0P 865843-42-1P 865843-43-2P
865843-44-3P 865843-45-4P 865843-46-5P 865843-47-6P 865843-48-7P
865843-49-8P 865843-50-1P 865843-51-2P 865843-52-3P 865843-53-4P
865843-54-5P 865843-55-6P 865843-56-7P 865843-57-8P 865843-58-9P
865843-59-0P 865843-60-3P 865843-61-4P 865843-62-5P 865843-63-6P
865843-64-7P 865843-65-8P 865843-66-9P 865843-67-0P 865843-68-1P
865843-69-2P 865843-70-5P 865843-71-6P 865843-72-7P 865843-73-8P
865843-74-9P 865843-75-0P 865843-76-1P 865843-77-2P 865843-78-3P
865843-79-4P 865843-80-7P 865843-81-8P 865843-82-9P 865843-83-0P
865843-84-1P 865843-85-2P 865843-86-3P 865843-87-4P 865843-88-5P

865843-89-6P 865843-90-9P 865843-91-0P 865843-92-1P 865843-93-2P
865843-94-3P 865843-95-4P 865843-96-5P 865843-97-6P 865843-98-7P
865843-99-8P 865844-00-4P 865844-02-6P 865844-03-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865844-04-8P 865844-05-9P 865844-06-0P 865844-07-1P 865844-08-2P
865844-09-3P 865844-10-6P 865844-11-7P 865844-12-8P 865844-13-9P
865844-14-0P 865844-15-1P 865844-16-2P 865844-17-3P 865844-18-4P
865844-19-5P 865844-20-8P 865844-21-9P 865844-22-0P 865844-23-1P
865844-24-2P 865844-25-3P 865844-26-4P 865844-27-5P 865844-28-6P
865844-29-7P 865844-30-0P 865844-31-1P 865844-32-2P 865844-33-3P
865844-34-4P 865844-35-5P 865844-36-6P 865844-37-7P 865844-38-8P
865844-39-9P 865844-40-2P 865844-41-3P 865844-42-4P 865844-43-5P
865844-44-6P 865844-45-7P 865844-46-8P 865844-47-9P 865844-48-0P
865844-49-1P 865844-50-4P 865844-51-5P 865844-52-6P 865844-53-7P
865844-54-8P 865844-55-9P 865844-56-0P 865844-57-1P 865844-58-2P
865844-59-3P 865844-60-6P 865844-61-7P 865844-62-8P 865844-63-9P
865844-64-0P 865844-65-1P 865844-66-2P 865844-67-3P 865844-68-4P
865844-69-5P 865844-70-8P 865844-71-9P 865844-72-0P 865844-73-1P
865844-74-2P 865844-75-3P 865844-76-4P 865844-77-5P 865844-78-6P
865844-79-7P 865844-80-0P 865844-81-1P 865844-82-2P 865844-83-3P
865844-84-4P 865844-85-5P 865844-86-6P 865844-87-7P 865844-88-8P
865844-89-9P 865844-90-2P 865844-91-3P 865844-92-4P 865844-93-5P
865844-94-6P 865844-95-7P 865844-96-8P 865844-97-9P 865844-98-0P
865844-99-1P 865845-00-7P 865845-01-8P 865845-02-9P 865845-03-0P
865845-04-1P 865845-05-2P 865845-06-3P 865845-07-4P 865845-08-5P
865845-09-6P 865845-10-9P 865845-11-0P 865845-12-1P 865845-13-2P
865845-14-3P 865845-15-4P 865845-16-5P 865845-17-6P 865845-18-7P
865845-19-8P 865845-20-1P 865845-21-2P 865845-22-3P 865845-23-4P
865845-24-5P 865845-25-6P 865845-26-7P 865845-27-8P 865845-28-9P
865845-29-0P 865845-30-3P 865845-31-4P 865845-32-5P 865845-33-6P
865845-34-7P 865845-35-8P 865845-36-9P 865845-37-0P 865845-38-1P
865845-39-2P 865845-40-5P 865845-41-6P 865845-42-7P 865845-43-8P
865845-44-9P 865845-45-0P 865845-46-1P 865845-47-2P 865845-48-3P
865845-49-4P 865845-50-7P 865845-51-8P 865845-52-9P 865845-53-0P
865845-54-1P 865845-55-2P 865845-56-3P 865845-57-4P 865845-58-5P
865845-59-6P 865845-60-9P 865845-61-0P 865845-62-1P 865845-63-2P
865845-64-3P 865845-65-4P 865845-66-5P 865845-67-6P 865845-68-7P
865845-69-8P 865845-70-1P 865845-71-2P 865845-72-3P 865845-73-4P
865845-74-5P 865845-75-6P 865845-76-7P 865845-77-8P 865845-78-9P
865845-79-0P 865845-80-3P 865845-81-4P 865845-82-5P 865845-83-6P
865845-84-7P 865845-85-8P 865845-86-9P 865845-87-0P 865845-88-1P
865845-89-2P 865845-90-5P 865845-91-6P 865845-92-7P 865845-93-8P
865845-94-9P 865845-95-0P 865845-96-1P 865845-97-2P 865845-98-3P
865845-99-4P 865846-00-0P 865846-01-1P 865846-02-2P 865846-03-3P
865846-04-4P 865846-05-5P 865846-06-6P 865846-07-7P 865846-08-8P
865846-09-9P 865846-10-2P 865846-11-3P 865846-12-4P 865846-13-5P
865846-14-6P 865846-15-7P 865846-16-8P 865846-17-9P 865846-18-0P
865846-19-1P 865846-20-4P 865846-21-5P 865846-22-6P 865846-23-7P
865846-24-8P 865846-25-9P 865846-26-0P 865846-27-1P 865846-28-2P
865846-29-3P 865846-30-6P 865846-31-7P 865846-32-8P 865846-33-9P
865846-34-0P 865846-35-1P 865846-36-2P 865846-37-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865846-38-4P 865846-39-5P 865846-40-8P 865846-41-9P 865846-42-0P
865846-43-1P 865846-44-2P 865846-45-3P 865846-46-4P 865846-47-5P
865846-48-6P 865846-49-7P 865846-50-0P 865846-51-1P 865846-52-2P
865846-53-3P 865846-54-4P 865846-55-5P 865846-56-6P 865846-57-7P
865846-58-8P 865846-59-9P 865846-60-2P 865846-61-3P 865846-62-4P
865846-63-5P 865846-64-6P 865846-65-7P 865846-66-8P 865846-67-9P
865846-68-0P 865846-69-1P 865846-70-4P 865846-71-5P 865846-72-6P
865846-73-7P 865846-74-8P 865846-75-9P 865846-76-0P 865846-77-1P

865846-78-2P 865846-79-3P 865846-80-6P 865846-81-7P 865846-82-8P
865846-83-9P 865846-84-0P 865846-85-1P 865846-86-2P 865846-87-3P
865846-88-4P 865846-89-5P 865846-90-8P 865846-91-9P 865846-92-0P
865846-93-1P 865846-94-2P 865846-95-3P 865846-96-4P 865846-97-5P
865846-98-6P 865846-99-7P 865847-00-3P 865847-01-4P 865847-02-5P
865847-03-6P 865847-04-7P 865847-05-8P 865847-06-9P 865847-07-0P
865847-08-1P 865847-09-2P 865847-10-5P 865847-11-6P 865847-12-7P
865847-13-8P 865847-14-9P 865847-15-0P 865847-16-1P 865847-17-2P
865847-18-3P 865847-19-4P 865847-20-7P 865847-21-8P 865847-22-9P
865847-23-0P 865847-24-1P 865847-25-2P 865847-26-3P 865847-27-4P
865847-28-5P 865847-29-6P 865847-30-9P 865847-31-0P 865847-32-1P
865847-33-2P 865847-34-3P 865847-35-4P 865847-36-5P 865847-37-6P
865847-38-7P 865847-39-8P 865847-40-1P 865847-41-2P 865847-42-3P
865847-43-4P 865847-44-5P 865847-45-6P 865847-46-7P 865847-47-8P
865847-48-9P 865847-49-0P 865847-50-3P 865847-51-4P 865847-52-5P
865847-53-6P 865847-54-7P 865847-55-8P 865847-56-9P 865847-57-0P
865847-58-1P 865847-59-2P 865847-60-5P 865847-61-6P 865847-62-7P
865847-63-8P 865847-64-9P 865847-65-0P 865847-66-1P 865847-67-2P
865847-68-3P 865847-69-4P 865847-70-7P 865847-71-8P 865847-72-9P
865847-73-0P 865847-74-1P 865847-75-2P 865847-76-3P 865847-77-4P
865847-78-5P 865847-79-6P 865847-80-9P 865847-81-0P 865847-82-1P
865847-83-2P 865847-84-3P 865847-85-4P 865847-86-5P 865847-87-6P
865847-88-7P 865847-89-8P 865847-90-1P 865847-91-2P 865847-92-3P
865847-93-4P 865847-94-5P 865847-95-6P 865847-96-7P 865847-97-8P
865847-98-9P 865847-99-0P 865848-00-6P 865848-01-7P 865848-02-8P
865848-03-9P 865848-04-0P 865848-05-1P 865848-06-2P 865848-07-3P
865848-08-4P 865848-09-5P 865848-10-8P 865848-11-9P 865848-12-0P
865848-13-1P 865848-14-2P 865848-15-3P 865848-16-4P 865848-17-5P
865848-18-6P 865848-19-7P 865848-20-0P 865848-21-1P 865848-22-2P
865848-23-3P 865848-24-4P 865848-25-5P 865848-26-6P 865848-27-7P
865848-28-8P 865848-29-9P 865848-30-2P 865848-31-3P 865848-32-4P
865848-33-5P 865848-34-6P 865848-35-7P 865848-36-8P 865848-37-9P
865848-40-4P 865848-41-5P 865848-44-8P 865848-45-9P 865848-46-0P
865848-47-1P 865848-48-2P 865848-49-3P 865848-50-6P 865848-51-7P
865848-52-8P 865848-53-9P 865848-54-0P 865848-55-1P 865848-56-2P
865848-57-3P 865848-58-4P 865848-59-5P 865848-60-8P 865848-61-9P
865848-62-0P 865848-63-1P 865848-64-2P 865848-65-3P 865848-66-4P
865848-67-5P 865848-68-6P 865848-69-7P 865848-70-0P 865848-71-1P
865848-72-2P 865848-73-3P 865848-74-4P 865848-75-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865848-76-6P 865848-77-7P 865848-78-8P 865848-79-9P 865848-80-2P
865848-81-3P 865848-82-4P 865848-83-5P 865848-84-6P 865848-85-7P
865848-86-8P 865848-87-9P 865848-88-0P 865848-89-1P 865848-90-4P
865848-91-5P 865848-92-6P 865848-93-7P 865848-94-8P 865848-95-9P
865848-96-0P 865848-97-1P 865848-98-2P 865848-99-3P 865849-00-9P
865849-01-0P 865849-02-1P 865849-03-2P 865849-04-3P 865849-05-4P
865849-06-5P 865849-07-6P 865849-08-7P 865849-09-8P 865849-10-1P
865849-11-2P 865849-12-3P 865849-13-4P 865849-14-5P 865849-15-6P
865849-16-7P 865849-17-8P 865849-18-9P 865849-19-0P 865849-20-3P
865849-21-4P 865849-22-5P 865849-23-6P 865849-24-7P 865849-25-8P
865849-26-9P 865849-27-0P 865849-28-1P 865849-29-2P 865849-30-5P
865849-31-6P 865849-32-7P 865849-33-8P 865849-34-9P 865849-35-0P
865849-36-1P 865849-37-2P 865849-38-3P 865849-39-4P 865849-40-7P
865849-41-8P 865849-42-9P 865849-43-0P 865849-44-1P 865849-45-2P
865849-46-3P 865849-47-4P 865849-48-5P 865849-49-6P 865849-50-9P
865849-51-0P 865849-52-1P 865849-53-2P 865849-54-3P 865849-55-4P
865849-56-5P 865849-57-6P 865849-58-7P 865849-59-8P 865849-60-1P
865849-61-2P 865849-62-3P 865849-63-4P 865849-64-5P 865849-65-6P
865849-66-7P 865849-67-8P 865849-68-9P 865849-69-0P 865849-70-3P
865849-71-4P 865849-72-5P 865849-73-6P 865849-74-7P 865849-75-8P
865849-76-9P 865849-77-0P 865849-78-1P 865849-79-2P 865849-80-5P
865849-81-6P 865849-82-7P 865849-83-8P 865849-84-9P 865849-85-0P
865849-86-1P 865849-87-2P 865849-88-3P 865849-89-4P 865849-90-7P

865849-91-8P 865849-92-9P 865849-93-0P 865849-94-1P 865849-95-2P
865849-96-3P 865849-97-4P 865849-98-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 108-49-6, 2,6-Dimethylpiperazine 110-85-0, Piperazine, reactions
140-75-0, 4-Fluorobenzylamine 776-04-5, 2-Trifluoromethylbenzenesulfonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865849-99-6P 865850-00-6P 865850-01-7P 865850-02-8P
865850-03-9P 865850-04-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865849-99-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

RN 865849-99-6 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-benzoyl-N-[(4-fluorophenyl)methyl]-5-nitro- (9CI) (CA INDEX NAME)



L41 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:612287 HCAPLUS
DN 143:133351
ED Entered STN: 15 Jul 2005
TI Preparation of pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
IN Salom, Barbara; D'Anello, Matteo; Brasca, Maria Gabriella; Giordano, Patrizia; Martina, Katia; Brookfield, Frederick Arthur; Trigg, William John; Boyd, Edward Andrew; Larard, Jonathan Anthony; Tesei, Dania
PA Pharmacia Italia S.p.A., Italy
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D-0471/04
ICS A61K-0031/437; A61P-0035/00
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005063747			2004WO-EP14676	20041223
W: AE, A...			BB, BG, BR, BW, BY, BZ, CA, CH,	
CN, C...			DZ, EC, EE, EG, ES, FI, GB, GD,	
GE, G...			IS, JP, KE, KG, KP, KR, KZ, LC,	
LK, L...			MG, MK, MN, MW, MX, MZ, NA, NI,	
NO, NZ, OM, PG, PH, PL, PT, RO,			RU, SC, SD, SE, SG, SK, SL, SY,	
TJ, TM, TN, TR, TT, TZ, UA, UG,			US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				

US2005209269

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US2005209269 A1 20050922 2004US-0020794 20041223

PRAI 2003GB-0030042 A 20031224

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005063747	ICM	C07D-0471/04
	ICS	A61K-0031/437; A61P-0035/00
	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61P0035-00 [ICS,7]
	ECLA	C07D471/04+221B+209B
US2005209269	IPCI	A61K0031-4745 [ICM,7]; C07D0471-02 [ICS,7]
	NCL	514/300.000
	ECLA	C07D471/04+221B+209B

OS MARPAT 143:133351

GI



I



II

AB The title compds. [I; R = Ra, CORa, CONRaRb, SO2Ra, CO2Ra; R1 = NRcRd, ORc; Ra, Rb, Rc and Rd = H, alkyl, cycloalkyl, etc.; R2 = alkyl, alkenyl, cycloalkyl, etc.] and pharmaceutically acceptable salts thereof together with pharmaceutical compns. comprising them, as well as combinatorial libraries of compds. I, are disclosed. Preparation of compds. I is described in ten examples. E.g., a multi-step synthesis of II, starting from 5-nitro-1H-pyrazolo[2,3-b]pyridine-3-carboxylic acid and 4-fluorobenzylamine-bearing resin, was given. The compds. I or compns. may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity (no biol. data given) such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders. Also disclosed is a process under SPS conditions for preparing the compds. I and chemical libraries comprising a plurality of them.

ST pyrrolopyridine prepn protein kinase inhibitor antitumor antiproliferative antiviral; Alzheimer disease pyrrolopyridine prepn; neurodegenerative disorder pyrrolopyridine prepn; combinatorial library pyrrolopyridine prepn protein kinase inhibitor

IT Sarcoma

(Kaposi's, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Antiarteriosclerotics

(antiatherosclerotics, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Prostate gland, disease
(benign hyperplasia, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hyperplasia
(benign prostatic, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, disease
(degeneration, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Lung, disease
(fibrosis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Thyroid gland, neoplasm
(follicle cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Chemotherapy
Radiotherapy
(for augmentation of; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Inflammation
Kidney, disease
(glomerulonephritis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Transplant and Transplantation
(host-vs.-graft reaction; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
(lymphoid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
(mesenchymal, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
(metastasis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Endocrine system, neoplasm
Neoplasm
(multiple endocrine neoplasia, treating familial adenomatosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
(myeloid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Mesenchyme
(neoplasm, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, neoplasm
(neurofibromatosis type 1, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Bone, neoplasm
Sarcoma
(osteosarcoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Digestive tract, neoplasm
(polyposis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Antitumor agents
Antiviral agents
Cell proliferation
Combinatorial chemistry
Combinatorial library

Human
Immunomodulators
Immunosuppressants
Nervous system agents
Transplant rejection
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Fibrosis
(pulmonary, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Artery, disease
(restenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Testis, neoplasm
(seminoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Blood vessel
(smooth muscle, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Carcinoma
(squamous cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Artery, disease
(stenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Carcinoma
(teratocarcinoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Alopecia
(treating or preventing radiotherapy-induced or chemotherapy-induced alopecia; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Atherosclerosis
(treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Alzheimer's disease
Antiarthritics
Arthritis
Autoimmune disease
Carcinoma
Melanoma
Nervous system, neoplasm
Psoriasis
(treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Infection
(viral, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Skin, disease
(xanthoma, treating keratoxanthoma; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Skin, disease
(xeroderma pigmentosum, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858340-95-1P 858340-96-2P 858340-97-3P 858340-98-4P 858340-99-5P
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858339-48-7P 858339-49-8P 858339-50-1P 858339-51-2P
858339-52-3P 858339-53-4P 858339-54-5P 858339-56-7P
858339-57-8P 858339-58-9P 858339-59-0P
858339-60-3P 858339-61-4P 858339-62-5P 858339-63-6P
858339-64-7P 858339-65-8P 858339-66-9P 858339-67-0P
858339-68-1P 858339-69-2P 858339-70-5P 858339-71-6P

858339-72-7P 858339-73-8P 858339-74-9P
858339-75-0P 858339-76-1P 858339-77-2P 858339-78-3P
858339-79-4P 858339-80-7P 858339-81-8P 858339-82-9P
858339-83-0P 858339-84-1P 858339-85-2P 858339-86-3P
858339-87-4P 858339-88-5P 858339-89-6P 858339-90-9P
858339-91-0P 858339-92-1P 858339-93-2P 858339-94-3P
858339-95-4P 858339-96-5P 858339-97-6P 858339-98-7P
858339-99-8P 858340-00-8P 858340-01-9P 858340-02-0P
858340-03-1P 858340-04-2P 858340-05-3P
858340-06-4P 858340-07-5P 858340-08-6P 858340-09-7P
858340-10-0P 858340-11-1P 858340-12-2P 858340-13-3P
858340-14-4P 858340-15-5P 858340-16-6P
858340-17-7P 858340-18-8P 858340-19-9P
858340-20-2P 858340-21-3P 858340-22-4P 858340-23-5P
858340-24-6P 858340-25-7P 858340-26-8P 858340-27-9P 858340-28-0P
858340-29-1P 858340-30-4P 858340-31-5P 858340-32-6P 858340-33-7P
858340-34-8P 858340-35-9P 858340-36-0P 858340-37-1P 858340-38-2P
858340-39-3P 858340-40-6P 858340-41-7P 858340-42-8P 858340-43-9P
858340-44-0P 858340-45-1P 858340-46-2P 858340-47-3P 858340-48-4P
858340-49-5P 858340-50-8P 858340-51-9P 858340-52-0P 858340-53-1P
858340-54-2P 858340-55-3P 858340-56-4P 858340-57-5P 858340-58-6P
858340-59-7P 858340-60-0P 858340-61-1P 858340-62-2P 858340-63-3P
858340-64-4P 858340-65-5P 858340-66-6P 858340-67-7P 858340-68-8P
858340-69-9P 858340-70-2P 858340-71-3P 858340-72-4P 858340-73-5P
858340-74-6P 858340-75-7P 858340-76-8P 858340-77-9P 858340-78-0P
858340-79-1P 858340-80-4P 858340-81-5P 858340-82-6P 858340-83-7P
858340-84-8P 858340-85-9P 858340-86-0P
858340-87-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 98-09-9, Benzenesulfonyl chloride 98-88-4, Benzoyl chloride 110-89-4, Piperidine, reactions 111-36-4, Butyl isocyanate 121-60-8, 4-(Acetylamino)benzenesulfonyl chloride 140-75-0, 4-Fluorobenzylamine 1885-14-9, Phenyl chloroformate
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858340-93-9P 858340-94-0P
RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 71-23-8, n-Propanol, reactions 34461-00-2, Sodium nitromalonaldehyde 245064-81-7 858341-00-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858340-88-2P 858340-89-3P 858340-90-6P 858340-91-7P 858340-92-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Graczyk, P; WO--03082868 A 2003 HCAPLUS
(2) Longo, A; WO---0198299 A 2001 HCAPLUS

IT 858339-48-7P 858339-49-8P 858339-52-3P
858339-53-4P 858339-57-8P 858339-58-9P
858339-59-0P 858339-60-3P 858339-65-8P
858339-66-9P 858339-69-2P 858339-70-5P
858339-73-8P 858339-74-9P 858339-75-0P
858339-76-1P 858339-81-8P 858339-82-9P
858339-85-2P 858339-86-3P 858339-89-6P
858339-90-9P 858339-91-0P 858339-92-1P
858339-96-5P 858339-97-6P 858340-00-8P
858340-01-9P 858340-04-2P 858340-05-3P

858340-06-4P 858340-07-5P 858340-12-2P
858340-13-3P 858340-15-5P 858340-16-6P
858340-17-7P 858340-18-8P 858340-19-9P
858340-20-2P 858340-85-9P 858340-86-0P
858340-87-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

RN 858339-48-7 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 858339-49-8 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 858339-52-3 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(3-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 858339-53-4 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(3-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 858339-57-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-1-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-58-9 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-1-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-59-0 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-1-methyl-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 858339-60-3 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-1-methyl-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 858339-65-8 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-66-9 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-69-2 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-70-5 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-73-8 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-74-9 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-75-0 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-methylphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-76-1 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-methylphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-81-8 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858339-82-9 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858339-85-2 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-methyl-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858339-86-3 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-methyl-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858339-89-6 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-5-[(methylsulfonyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-90-9 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858339-91-0 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858339-92-1 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858339-96-5 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858339-97-6 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858340-00-8 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-01-9 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858340-04-2 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[(methylsulfonyl)amino]-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-05-3 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858340-06-4 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-methylphenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-07-5 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-methylphenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 858340-12-2 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 858340-13-3 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[[(propylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 858340-15-5 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-(phenylmethyl)-5-[[(propylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 858340-16-6 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[[(propylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 858340-17-7 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 858340-18-8 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 858340-19-9 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 858340-20-2 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[[(propylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 858340-85-9 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-86-0 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[[[4-(acetylamino)phenyl]sulfonyl]amino]-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-87-1 HCAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[[(butylamino)carbonyl]amino]-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



=> d all fhitstr l41 3-4

L41 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:927204 HCAPLUS
DN 141:395538
ED Entered STN: 04 Nov 2004
TI Preparation of 7-azaindolylglyoxylamides as phosphodiesterase IV inhibitors.
IN **Hoefgen, Norbert; Kuss, Hildegard; Olbrich, Matthias; Egerland, Ute; Rundfeldt, Chris; Steinike, Karin; Schindler, Rudolf**
PA **Elbion A.-G., Germany**
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM C07D-0471/04
ICS A61K-0031/437; A61P-0035/00
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004094416	A1	20041104	2004WO-EP04339	20040423 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE--10318610	A1	20041111	2003DE-1018610	20030424 <--
	US2004224971	A1	20041111	2004US-0826136	20040416 <--
	CA---2523063	AA	20041104	2004CA-2523063	20040423 <--
	EP---1613627	A1	20060111	2004EP-0729102	20040423 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	2003DE-1018610	A	20030424 <--		
	2004WO-EP04339	W	20040423		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004094416	ICM	C07D-0471/04
	ICS	A61K-0031/437; A61P-0035/00
	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61P0035-00 [ICS,7]
	ECLA	C07D471/04+221B+209B <--
DE--10318610	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61P0019-00 [ICS,7]; A61P0011-00 [ICS,7]; A61P0031-00 [ICS,7]; A61P0035-00 [ICS,7]
	ECLA	C07D471/04+221B+209B <--
US2004224971	IPCI	C07D0471-02 [ICM,7]; C07D0043-02 [ICS,7]; A61K0031-4745 [ICS,7]; A61K0031-4439 [ICS,7]
	NCL	514/300.000
	ECLA	C07D471/04+221B+209B <--
CA---2523063	IPCI	C07D0471-04 [ICM,7]; A61P0035-00 [ICS,7]; A61K0031-437 [ICS,7]
	ECLA	C07D471/04+221B+209B <--
EP---1613627	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61P0035-00 [ICS,7]
	ECLA	C07D471/04+221B+209B <--

OS MARPAT 141:395538

GI



I

AB Title compds. [I; A = N, N-oxide group; B = C, N, N-oxide group; R1 = (substituted) alkyl, alkenyl; R2 = H, alkyl; R3, R4 = H, alkyl, OH, SH, NH2, NO2, cyano, SO3H, CO2H, alkoxycarbonyl, halo, alkoxy, alkylthio, (substituted) Ph, pyridyl, etc.], were prepared Thus, N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-azaindol-3-yl]glyoxylic acid

amide in CH2Cl2 was treated dropwise with m-chloroperbenzoic acid in HOAc followed by stirring for 7 days to give 9.4% N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylic acid amide. I inhibited phosphodiesterase 4 with IC50's in the range of 10-10 M to 10-5 M.

ST azaindolylglyoxylamide prepn phosphodiesterase inhibitor; hyperproliferation treatment azaindolylglyoxylamide prepn; eosinophil neutrophil connected disease treatment pyridinyl azaindolylglyoxylamide

IT Cell proliferation
(hyperproliferative disorder treatment; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT Drug delivery systems
Human
(preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT Eosinophil
(treatment of diseases connected with eosinophils; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT Neutrophil
(treatment of diseases connected with neutrophils; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT **785815-36-3P 785815-37-4P 785815-38-5P**
785815-39-6P 785815-40-9P 785815-41-0P
785815-42-1P 785815-43-2P 785815-44-3P
785815-45-4P 785815-46-5P 785815-47-6P
785815-48-7P 785815-49-8P 785815-50-1P
785815-51-2P 785815-52-3P 785815-53-4P
785815-54-5P 785815-55-6P 785815-56-7P
785815-57-8P 785815-58-9P 785815-59-0P
785815-60-3P 785815-61-4P 785815-62-5P
785815-63-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT 9036-21-9, Phosphodiesterase IV
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT **418794-42-0 785815-64-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Asta Medica Ag; WO---9809946 A 1998 HCAPLUS
(2) Dresden, A; DE--19818964 A 1999 HCAPLUS
(3) Polymeropoulos, E; WO---0234747 A 2002 HCAPLUS
(4) Rahm; WO---9611929 A 1996 HCAPLUS

IT **785815-36-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

RN 785815-36-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-α-oxo-, 7-oxide (9CI) (CA INDEX NAME)



L41 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:332190 HCAPLUS
DN 136:340669
ED Entered STN: 03 May 2002
TI Novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors
IN **Hoefgen, Norbert**; **Egerland, Ute**; Kronbach, Thomas; Marx, Degenhard; Szelenyi, Stefan; **Kuss, Hildegard**; Polymeropoulos, Emmanuel
PA Arzneimittelwerk Dresden Gmbh, Germany
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM C07D-0471/04
ICS A61P-0011/00; A61K-0031/40
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002034747	A1	20020502	2001WO-EP12376	20011025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE--10053275	A1	20020502	2000DE-1053275	20001027
CA---2428468	AA	20020502	2001CA-2428468	20011025
AU2002021753	A5	20020506	2002AU-0021753	20011025
EP---1330455	A1	20030730	2001EP-0988718	20011025
EP---1330455	B1	20050803		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE-200300166	A	20030815	2003EE-0000166	20011025
BR2001014903	A	20031014	2001BR-0014903	20011025
JP2004512337	T2	20040422	2002JP-0537738	20011025
NZ----525369	A	20040924	2001NZ-0525369	20011025
AT----301121	E	20050815	2001AT-0988718	20011025
RU---2268887	C2	20060127	2003RU-0115621	20011025
NO2003001722	A	20030414	2003NO-0001722	20030414
BG----107725	A	20040831	2003BG-0107725	20030416
ZA2003003236	A	20030731	2003ZA-0003236	20030425
HR2003000427	A1	20030831	2003HR-0000427	20030526

US2004106641	A1	20040603	2003US-0399051	20030617
PRAI 2000DE-1053275	A	20001027		
2000US-244342P	P	20001030		
2001WO-EP12376	W	20011025		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002034747	ICM	C07D-0471/04
	ICS	A61P-0011/00; A61K-0031/40
	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
	ECLA	C07D471/04+221B+209B
DE--10053275	IPCI	C07D0471-04 [ICM,7]; A61K0031-495 [ICS,7]; A61K0031-505 [ICS,7]
	ECLA	C07D471/04+221B+209B
CA---2428468	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
AU2002021753	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
EP---1330455	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
	ECLA	C07D471/04+221B+209B
EE-200300166	IPCI	A61K0031-40 [ICM,7]; A61P0011-00 [ICS,7]; C07D0471-04 [ICS,7]
BR2001014903	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
JP2004512337	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61K0031-444 [ICS,7]; A61K0031-496 [ICS,7]; A61K0031-513 [ICS,7]; A61K0031-5377 [ICS,7]; A61K0031-541 [ICS,7]; A61P0001-04 [ICS,7]; A61P0003-10 [ICS,7]; A61P0005-48 [ICS,7]; A61P0007-12 [ICS,7]; A61P0009-10 [ICS,7]; A61P0011-00 [ICS,7]; A61P0011-02 [ICS,7]; A61P0011-06 [ICS,7]; A61P0013-00 [ICS,7]; A61P0013-04 [ICS,7]; A61P0013-08 [ICS,7]; A61P0013-12 [ICS,7]; A61P0015-10 [ICS,7]; A61P0017-00 [ICS,7]; A61P0017-06 [ICS,7]; A61P0019-02 [ICS,7]; A61P0019-08 [ICS,7]; A61P0019-10 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-18 [ICS,7]; A61P0025-28 [ICS,7]; A61P0025-30 [ICS,7]; A61P0027-14 [ICS,7]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-18 [ICS,7]; A61P0033-00 [ICS,7]; A61P0033-02 [ICS,7]; A61P0037-02 [ICS,7]; A61P0037-06 [ICS,7]; A61P0037-08 [ICS,7]; A61P0039-02 [ICS,7]; A61P0043-00 [ICS,7]
	FTERM	4C065/AA04; 4C065/BB04; 4C065/CC01; 4C065/DD02; 4C065/EE02; 4C065/HH01; 4C065/JJ01; 4C065/KK01; 4C065/LL01; 4C065/PP12; 4C065/PP15; 4C065/PP16; 4C065/PP17; 4C065/QQ04; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC17; 4C086/BC42; 4C086/BC50; 4C086/BC73; 4C086/BC88; 4C086/CB05; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA01; 4C086/ZA12; 4C086/ZA15; 4C086/ZA16; 4C086/ZA33; 4C086/ZA34; 4C086/ZA45; 4C086/ZA59; 4C086/ZA60; 4C086/ZA66; 4C086/ZA68; 4C086/ZA81; 4C086/ZA84; 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB07; 4C086/ZB08; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB33; 4C086/ZB35; 4C086/ZB37; 4C086/ZB38; 4C086/ZC02; 4C086/ZC20; 4C086/ZC35; 4C086/ZC37; 4C086/ZC55
NZ----525369	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
AT----301121	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
	ECLA	C07D471/04+221B+209B
RU---2268887	IPCI	C07D0471-04 [I,A]; A61P0011-00 [I,A]; A61K0031-40 [I,A]
NO2003001722	IPCI	C07D0471-04 [ICM,7]
BG----107725	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40

		[ICS,7]
ZA2003003236	IPCI	C07D [ICM,7]; A61P [ICS,7]; A61K [ICS,7]
HR2003000427	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
US2004106641	IPCI	A61K0031-4745 [ICM,7]
	NCL	514/300.000
	ECLA	C07D471/04+221B+209B

OS CASREACT 136:340669; MARPAT 136:340669

GI



I

AB 7-Azaindoles I [n = 1, 2; R1 = (un)substituted alkyl, alkenyl; R2, R3 = H, (un)substituted alkyl, Ph, pyridyl, uracilyl, triazolyl; NR2R3 = morpholino, thiomorpholino, thiomorpholine S,S-dioxide, 4-methylpiperazino] were prepared for use as PDE-4 inhibitors. Thus, 1-cyclopropylmethyl-7-azaindole-3-carboxylic acid was converted to the acid chloride and treated with 4-aminomethylpyridine to give the amide which had an IC50 for PDE-4 inhibition of 0.710 μmol./L.

ST azaindolecarboxamide prepn phosphodiesterase inhibitor

IT Eosinophil
Neutrophil
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 9036-21-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IV; preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT **418794-16-8P** 418794-19-1P **418794-38-4P**
418794-40-8P **418794-42-0P** **418794-44-2P**
418794-46-4P **418794-47-5P** **418794-49-7P**
418794-55-5P **418794-57-7P** **418794-59-9P**
418794-61-3P **418794-63-5P** **418794-64-6P**
418794-66-8P **418794-73-7P** **418794-82-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 61-82-5, 1H-1,2,4-Triazol-3-amine 94-09-7, Ethyl 4-aminobenzoate 109-01-3, N-Methylpiperazine 110-91-8, Morpholine, reactions 111-95-5 150-13-0, 4-Aminobenzoic acid 608-31-1, 2,6-Dichloroaniline 1003-40-3, 4-Aminopyridine hydrochloride 3731-53-1, 4-Aminomethylpyridine 6270-46-8, 5-Amino-6-methyluracil 6315-89-5, 3,4-Dimethoxyaniline 35965-29-8 35965-33-4 39093-93-1, Thiomorpholine S,S-dioxide 55276-24-9, 5-Amino-1,3,6-trimethyluracil 142648-55-3 418794-90-8, 1-(Cyclopropylmethyl)-7-azaindole-3-carboxylic acid 418794-93-1, 1-Isobutyl-7-azaindole-3-carboxylic acid 418794-94-2, 1-Hexyl-7-azaindole-3-carboxylic acid 418794-96-4 418794-98-6 418795-00-3 418795-02-5 418795-04-7, 4-Aminomethyl-3,5-dichloropyridine 418795-06-9 418795-10-5 418795-13-8 418795-15-0 418795-17-2 418795-19-4 418795-20-7 418795-22-9 418795-24-1 418795-26-3 418795-27-4 418795-29-6 418795-30-9 418795-32-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 418794-92-0P 418795-08-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 418794-22-6P 418794-24-8P 418794-25-9P 418794-27-1P
418794-29-3P 418794-30-6P 418794-32-8P 418794-34-0P 418794-36-2P
418794-51-1P 418794-53-3P 418794-54-4P
418794-68-0P 418794-70-4P 418794-71-5P
418794-75-9P 418794-76-0P 418794-78-2P 418794-80-6P
418794-84-0P 418794-86-2P 418794-88-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Fujisawa Pharmaceut Co Ltd; JP--10120681 A 1998 HCAPLUS
(2) Mouaddib, A; SYNTHESIS 2000, 4, P549 HCAPLUS
(3) Smithkline Beecham Plc; WO---9611929 A 1996 HCAPLUS
(4) Sterling Drug Inc; GB---1141949 A 1969 HCAPLUS

IT 418794-16-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

RN 418794-16-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-(cyclopropylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



=> b uspatall
FILE 'USPATFULL' ENTERED AT 13:10:30 ON 31 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:10:30 ON 31 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitstr hitrn l40 tot

L40 ANSWER 1 OF 4 USPATFULL on STN
AN 2005:293602 USPATFULL
TI Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process

for their preparation and pharmaceutical compositions comprising them
IN Salom, Barbara, Vedano al Lambro (MI), ITALY
D'Anello, Matteo, Novate Milanese (MI), ITALY
Brasca, Maria Gabriella, Milano, ITALY
Giordano, Patrizia, Cuneo, ITALY
Martina, Katia, Novara, ITALY
Angelucci, Francesco, Milano, ITALY
Brookfield, Frederick Arthur, Wallingford, UNITED KINGDOM
Trigg, William John, Abingdon, UNITED KINGDOM
Boyd, Edward Andrew, Reading, UNITED KINGDOM
Larard, Jonathan Anthony, Pocklington, UNITED KINGDOM
PA Pharmacia Italia S.p.A., Milano, ITALY (non-U.S. corporation)
PI US2005256151 A1 20051117
AI 2004US-0020793 A1 20041223 (11)
PRAI 2003GB-0030043 20031224
DT Utility
FS APPLICATION
LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **865849-99-6P**
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
RN 865849-99-6 USPATFULL
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-benzoyl-N-[(4-fluorophenyl)methyl]-5-nitro- (9CI) (CA INDEX NAME)



IT **865849-99-6P**
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

L40 ANSWER 2 OF 4 USPATFULL on STN
AN 2005:241264 USPATFULL
TI Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IN Salom, Barbara, Vedano al Lambro (MI), ITALY
D'Anello, Matteo, Novate Milanese (MI), ITALY
Brasca, Maria Gabriella, Milano, ITALY
Giordano, Patrizia, Cuneo, ITALY
Martina, Katia, Novara, ITALY
Tesei, Dania, Ancona, ITALY

Brookfield, Frederick Arthur, Wallingford, UNITED KINGDOM
Trigg, William John, Abingdon, UNITED KINGDOM
Boyd, Edward Andrew, Reading, UNITED KINGDOM
Larard, Jonathan Anthony, Pocklington, UNITED KINGDOM
PA Pharmacia Italia S.p.A., Milano, ITALY (non-U.S. corporation)
PI US2005209269 A1 20050922
AI 2004US-0020794 A1 20041223 (11)
PRAI 2003GB-0030042 20031224
DT Utility
FS APPLICATION
LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 858339-48-7P
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
RN 858339-48-7 USPATFULL
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



IT 858339-48-7P 858339-49-8P 858339-52-3P
858339-53-4P 858339-57-8P 858339-58-9P
858339-59-0P 858339-60-3P 858339-65-8P
858339-66-9P 858339-69-2P 858339-70-5P
858339-73-8P 858339-74-9P 858339-75-0P
858339-76-1P 858339-81-8P 858339-82-9P
858339-85-2P 858339-86-3P 858339-89-6P
858339-90-9P 858339-91-0P 858339-92-1P
858339-96-5P 858339-97-6P 858340-00-8P
858340-01-9P 858340-04-2P 858340-05-3P
858340-06-4P 858340-07-5P 858340-12-2P
858340-13-3P 858340-15-5P 858340-16-6P
858340-17-7P 858340-18-8P 858340-19-9P
858340-20-2P 858340-85-9P 858340-86-0P
858340-87-1P
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

L40 ANSWER 3 OF 4 USPATFULL on STN
AN 2004:286803 USPATFULL
TI 7-azaindoles and the use thereof as therapeutic agents
IN Hofgen, Nobert, Ottendorf-Okrilla, GERMANY, FEDERAL REPUBLIC OF
Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF

Olbrich, Matthias, Moritzburg, GERMANY, FEDERAL REPUBLIC OF
Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF
Rundfeldt, Chris, Coswig, GERMANY, FEDERAL REPUBLIC OF
Steinike, Karin, Radebul, GERMANY, FEDERAL REPUBLIC OF
Schindler, Rudolf, Dresden, GERMANY, FEDERAL REPUBLIC OF

PI US2004224971 A1 20041111
AI 2004US-0826136 A1 20040416 (10)
PRAI DE 2003-10318610 20030424
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1093

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **785815-36-3P**
(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

RN 785815-36-3 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-α-oxo-, 7-oxide (9CI) (CA INDEX NAME)



IT **785815-36-3P 785815-37-4P 785815-38-5P**
785815-39-6P 785815-40-9P 785815-41-0P
785815-42-1P 785815-43-2P 785815-44-3P
785815-45-4P 785815-46-5P 785815-47-6P
785815-48-7P 785815-49-8P 785815-50-1P
785815-51-2P 785815-52-3P 785815-53-4P
785815-54-5P 785815-55-6P 785815-56-7P
785815-57-8P 785815-58-9P 785815-59-0P
785815-60-3P 785815-61-4P 785815-62-5P
785815-63-6P
(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

IT **418794-42-0 785815-64-7**
(preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)

L40 ANSWER 4 OF 4 USPATFULL on STN

AN 2004:139465 USPATFULL
TI Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
IN Hofgen, Norbert, Ottendorf-Okrilla, GERMANY, FEDERAL REPUBLIC OF
Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF
Kronbach, Thomas, Radebeul, GERMANY, FEDERAL REPUBLIC OF
Marx, Degenhard, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
Szelenyi, Stefan, Schwaig, GERMANY, FEDERAL REPUBLIC OF
Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF
Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PI US2004106641 A1 20040603
AI 2003US-0399051 A1 20030617 (10)
2001WO-EP12376 20011025
PRAI DE 2000-10053275 20001027
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1214
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to new 7-azaindoles, their use as inhibitors of phosphodiesterase 4 and to methods for their synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **418794-16-8P**
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)
RN 418794-16-8 USPATFULL
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-(cyclopropylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



IT **418794-16-8P 418794-38-4P 418794-40-8P**
418794-42-0P 418794-44-2P 418794-46-4P
418794-47-5P 418794-49-7P 418794-55-5P
418794-57-7P 418794-59-9P 418794-61-3P
418794-63-5P 418794-64-6P 418794-66-8P
418794-73-7P 418794-82-8P
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)
IT **418794-25-9P 418794-51-1P 418794-53-3P**
418794-54-4P 418794-68-0P 418794-70-4P
418794-71-5P 418794-84-0P 418794-86-2P
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

```
=> d his

     (FILE 'HOME' ENTERED AT 11:57:09 ON 31 JAN 2006)

     FILE 'HCAPLUS' ENTERED AT 11:57:19 ON 31 JAN 2006
L1             1 US2004224971/PN OR (US2004-826136# OR DE2003-10318610#)/AP,PRN
                 E HOFGEN N/AU
L2            12 E3-4
                 E HOEFGEN N/AU
L3            31 E3-4
                 E KUSS H/AU
L4            51 E3-6,E11
                 E OLBRICH M/AU
L5            24 E3-4,E7
                 E EGERLAND U/AU
L6            20 E3-4
                 E RUNDFELDT C/AU
L7            71 E3-4
                 E STEINKE K/AU
                 E STEINIKE K/AU
L8             6 E3-4
                 E SCHINDLER R/AU
L9           775 E3-11
                 E SCHINDLER RUD/AU
L10           28 E4-7
L11           17 ELBION/CS,PA
                 E ELBION/CS,PA
L12           17 E3-14

     FILE 'REGISTRY' ENTERED AT 12:06:35 ON 31 JAN 2006

     FILE 'HCAPLUS' ENTERED AT 12:07:37 ON 31 JAN 2006
L13              TRA L1 1- RN :        31 TERMS

     FILE 'REGISTRY' ENTERED AT 12:07:38 ON 31 JAN 2006
L14           31 SEA L13
L15              STR
L16            2 L15
L17           52 L15 FULL
                 SAV TEM BAL136F0/A L17
L18           30 L17 AND L14

     FILE 'HCAPLUS' ENTERED AT 12:27:13 ON 31 JAN 2006
L19            2 L17
L20            2 L1-12 AND L19

     FILE 'USPATFULL, USPAT2' ENTERED AT 12:31:30 ON 31 JAN 2006
L21            2 L17
                 E HOEFGEN N/AU
                 E HOFGEN N/AU

     FILE 'HCAOLD' ENTERED AT 12:33:43 ON 31 JAN 2006
L22            0 L17

     FILE 'REGISTRY' ENTERED AT 12:46:26 ON 31 JAN 2006
L23              STR L15
L24            0 L23
L25           98 L23 FULL
L26           46 L25 NOT L17
L27           30 L25 AND L14

     FILE 'HCAPLUS' ENTERED AT 12:55:05 ON 31 JAN 2006
L28            3 L26
L29            1 L28 AND L1-12
L30            4 L19,L28 AND L1-12,L19-20,L28-29
```

```
     FILE 'USPATFULL, USPAT2' ENTERED AT 12:58:53 ON 31 JAN 2006
L31             3 L26
L32             4 L21,L31

     FILE 'HCAOLD' ENTERED AT 12:59:35 ON 31 JAN 2006
L33             0 L26

     FILE 'REGISTRY' ENTERED AT 13:00:51 ON 31 JAN 2006
L34               STR L23
L35             1 L34
L36           101 L34 FULL
L37             3 L36 NOT L25

     FILE 'HCAPLUS' ENTERED AT 13:05:47 ON 31 JAN 2006
L38             1 L37

     FILE 'USPATFULL, USPAT2' ENTERED AT 13:06:16 ON 31 JAN 2006
L39             1 L37
L40             4 L32,L39

     FILE 'HCAPLUS' ENTERED AT 13:07:15 ON 31 JAN 2006
L41             4 L30,L38

     FILE 'HCAOLD' ENTERED AT 13:07:34 ON 31 JAN 2006
L42             0 L37

=>
```